Clinical trial
A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia
NCT00452374 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 30, 2004
- Completion date
- January 31, 2011
- Enrollment
- 48 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.